Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
68
ARQT Quote, Financials, Valuation and Earnings
Last price:
$29.44
Seasonality move
:
61.76%
Day range:
$29.14 - $29.55
52-week range:
$11.13 - $31.77
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.83x
P/B ratio:
22.81x
Volume:
1.4M
Avg. volume:
2.3M
1-year change:
96.46%
Market cap:
$3.6B
Revenue:
$196.5M
EPS (TTM):
-$0.35
Analysts' Opinion
-
Consensus RatingArcutis Biotherapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $31.63, Arcutis Biotherapeutics, Inc. has an estimated upside of 7.9% from its current price of $29.45.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $29.00 representing 100% downside risk from its current price of $29.45.
Fair Value
-
According to the consensus of 6 analysts, Arcutis Biotherapeutics, Inc. has 7.9% upside to fair value with a price target of $31.63 per share.
ARQT vs. S&P 500
-
Over the past 5 trading days, Arcutis Biotherapeutics, Inc. has overperformed the S&P 500 by 1.29% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Arcutis Biotherapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Arcutis Biotherapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Arcutis Biotherapeutics, Inc. reported revenues of $99.2M.
Earnings Growth
-
Arcutis Biotherapeutics, Inc. has grown year-over-year earnings for 10 quarters straight. In the most recent quarter Arcutis Biotherapeutics, Inc. reported earnings per share of $0.06.
Enterprise value:
3.5B
EV / Invested capital:
12.92x
Price / LTM sales:
11.83x
EV / EBIT:
--
EV / Revenue:
11.05x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-72.81x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$286M
Return On Assets:
-11.96%
Net Income Margin (TTM):
-13.94%
Return On Equity:
-29.4%
Return On Invested Capital:
-15.75%
Operating Margin:
8.59%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $49M | $138.7M | $317.9M | $44.8M | $99.2M | |
| Gross Profit | $45.1M | $124M | $286M | $39.3M | $90.5M | |
| Operating Income | -$248.4M | -$181.9M | -$38.2M | -$39.1M | $8.5M | |
| EBITDA | -$246.7M | -$179.4M | -$33.5M | -$37.6M | $9.1M | |
| Diluted EPS | -$4.37 | -$1.79 | -$0.35 | -$0.33 | $0.06 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $381.8M | $496.7M | $281.5M | $423.7M | $349.2M | |
| Total Assets | $387M | $508.9M | $293M | $437.4M | $371M | |
| Current Liabilities | $19.1M | $37.1M | $41.9M | $172.4M | $99.8M | |
| Total Liabilities | $24M | $238.1M | $246.2M | $280.7M | $212.9M | |
| Total Equity | $363M | $270.8M | $46.7M | $156.6M | $158.1M | |
| Total Debt | $5.2M | $201M | $204.4M | $207.4M | $113.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$261.9M | -$167.7M | -$32.6M | -$34.7M | -$1.8M | |
| Cash From Investing | $284.6M | -$68.2M | $38.8M | $84.8M | -$25.2M | |
| Cash From Financing | $3M | $262.9M | -$94.2M | $394K | $1.5M | |
| Free Cash Flow | -$262.4M | -$167.8M | -$48.2M | -$34.8M | -$1.8M | |
ARQT
Sector
Market Cap
$3.6B
$28.1M
Price % of 52-Week High
92.67%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
0.57%
-1.49%
1-Year Price Total Return
95.79%
-17.13%
Beta (5-Year)
1.693
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$28.78
200-day SMA
Buy
Level
$18.14
Bollinger Bands (100)
Buy
Level
16.41 - 27.23
Chaikin Money Flow
Sell
Level
-6.1M
20-day SMA
Sell
Level
$29.65
Relative Strength Index (RSI14)
Buy
Level
56.79
ADX Line
Buy
Level
26.89
Williams %R
Neutral
Level
-58.2249
50-day SMA
Buy
Level
$26.39
MACD (12, 26)
Buy
Level
0.63
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
127.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.8708)
Sell
CA Score
(Annual)
Level (-2.5769)
Sell
Beneish M-Score
(Annual)
Level (-0.6182)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.0814)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
Stock Forecast FAQ
In the current month, ARQT has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ARQT average analyst price target in the past 3 months is $31.63.
-
Where Will Arcutis Biotherapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Arcutis Biotherapeutics, Inc. share price will rise to $31.63 per share over the next 12 months.
-
What Do Analysts Say About Arcutis Biotherapeutics, Inc.?
Analysts are divided on their view about Arcutis Biotherapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Arcutis Biotherapeutics, Inc. is a Sell and believe this share price will drop from its current level to $29.00.
-
What Is Arcutis Biotherapeutics, Inc.'s Price Target?
The price target for Arcutis Biotherapeutics, Inc. over the next 1-year time period is forecast to be $31.63 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ARQT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Arcutis Biotherapeutics, Inc. is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ARQT?
You can purchase shares of Arcutis Biotherapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Arcutis Biotherapeutics, Inc. shares.
-
What Is The Arcutis Biotherapeutics, Inc. Share Price Today?
Arcutis Biotherapeutics, Inc. was last trading at $29.44 per share. This represents the most recent stock quote for Arcutis Biotherapeutics, Inc.. Yesterday, Arcutis Biotherapeutics, Inc. closed at $29.45 per share.
-
How To Buy Arcutis Biotherapeutics, Inc. Stock Online?
In order to purchase Arcutis Biotherapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ARQT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ARQT
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
22.81x
1.81x
Price / LTM sales
11.83x
1.59x
Growth Metrics
ARQT
Sector
Revenue growth
121.69%
4.62%
Earnings growth
116.7%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.09
-$0.21
Profitability
ARQT
Sector
Profitability FY 2024
$177.4M
$3.6M
Return on invested capital
-15.75%
-31.84%
Return on assets
-11.96%
-27.96%
Return on equity
-29.4%
-37.63%
Earnings Date
Last Earnings Date
Oct
28
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Jan
27
Balance Sheet
ARQT
Sector
Total cash
$191.4M
$26.4M
Short term investments
$156.6M
$25.7M
Total assets
$348.9M
$76.9M
Long term debt
$113.8M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
